دورية أكاديمية
Association between statin intensity and femoropopliteal stent primary patency in peripheral arterial disease
| العنوان: | Association between statin intensity and femoropopliteal stent primary patency in peripheral arterial disease |
|---|---|
| المؤلفون: | Elisabeth R. Seyferth, Helen Song, Ansar Z. Vance, Timothy W. I. Clark |
| المصدر: | CVIR Endovascular, Vol 7, Iss 1, Pp 1-9 (2024) |
| بيانات النشر: | SpringerOpen, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Diseases of the circulatory (Cardiovascular) system |
| مصطلحات موضوعية: | Peripheral arterial disease, Femoropopliteal stent, Restenosis, Statin, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| الوصف: | Abstract Background Statins are widely used in coronary and peripheral arterial disease, but their impact on patency of stents placed for peripheral arterial disease is not well-studied. The purpose of this study was to evaluate femoropopliteal stent primary patency according to statin intensity at the time of stent placement and compare this effect to other covariates that may influence stent patency. Materials and methods A retrospective review identified 278 discrete femoropopliteal stent constructs placed in 216 patients over a 10-year period; Rutherford categories were 2 (3.6%), 3 (12.9%), 4 (21.2%), 5 (49.6%), and 6 (12.6%). Stent locations were common femoral (1.8%), common femoral/superficial femoral (0.7%), superficial femoral (50.7%), superficial femoral/popliteal (32.7%) and popliteal (14.0%) arteries; 63.3% of stents were paclitaxel-eluting. Primary patency of each stent construct was determined with duplex ultrasound, angiography, or computed tomographic angiography. Greater than 50% restenosis or stent occlusion was considered loss of patency. Cox proportional hazard and Kaplan–Meier modeling were used to assess the effect of statin use and additional covariates on stent patency. Results Patients on any statin at the time of stent placement were half as likely to undergo loss of primary unassisted patency as patients on no statin therapy (hazard ratio, 0.53; 95% confidence interval, 0.19–0.87; P = .004). Moderate/high intensity statin therapy conferred 17 additional months of median stent patency compared to the no statin group. Antiplatelet therapy, anticoagulant therapy, drug-eluting stents (versus bare metal or covered stents), and Rutherford class were not predictive of stent patency (P = 0.52, 0.85, 0.58, and 0.82, respectively). Conclusion Use of statin therapy at the time of femoropopliteal stent placement was the most predictive examined variable influencing primary unassisted patency. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2520-8934 46868682 |
| Relation: | https://doaj.org/toc/2520-8934 |
| DOI: | 10.1186/s42155-024-00472-4 |
| URL الوصول: | https://doaj.org/article/61d314e8298e46868682c5a29c460d8b |
| رقم الأكسشن: | edsdoj.61d314e8298e46868682c5a29c460d8b |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 25208934 46868682 |
|---|---|
| DOI: | 10.1186/s42155-024-00472-4 |